After years of delays and setbacks, the lentiviral vector gene therapy platform has secured two FDA approvals. The agency approved bluebird bio’s betibeglogene autotemcel for severe β-thalassemia in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results